Axis-Shield and Bio-Rad Sign Agreement for Commercialization of Sepsis Biomarker | GenomeWeb

Scottish diagnostics firm Axis-Shield announced this week an agreement to allow Bio-Rad Laboratories an option to commercialize heparin binding protein as a biomarker for severe sepsis.

Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments worldwide.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.